Login / Signup

A GLP-1/glucagon (GCG)/CCK 2 receptors tri-agonist provides new therapy for obesity and diabetes.

Songfeng ZhaoZhiming YanYue DuZeyun LiChunli TangLin JingLidan SunQimeng YangXueling TangYongliang YuanJing HanNeng Jiang
Published in: British journal of pharmacology (2022)
These results demonstrate the therapeutic potential of xGLP-1/GCG/gastrin for the treatment of obesity and diabetes.
Keyphrases
  • type diabetes
  • insulin resistance
  • glycemic control
  • weight loss
  • metabolic syndrome
  • cardiovascular disease
  • high fat diet induced
  • weight gain
  • adipose tissue
  • skeletal muscle
  • body mass index
  • smoking cessation